Literature DB >> 5636740

Carcinoma of prostate: response of plasma luteinizing hormone and testosterone to oestrogen therapy.

A Alder, H Burger, J Davis, A Dulmanis, B Hudson, G Sarfaty, W Straffon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5636740      PMCID： PMC1984910          DOI： 10.1136/bmj.1.5583.28

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  9 in total

1.  THE EFFECT OF DIETHYLSTILBOESTROL ON TESTICULAR 17ALPHA-HYDROXYLASE AND 17-DESMOLASE ACTIVITIES IN BALB/C MICE.

Authors:  L T SAMUELS; J G SHORT; R A HUSEBY
Journal:  Acta Endocrinol (Copenh)       Date:  1964-04

2.  IMMUNOASSAY OF HUMAN GROWTH HORMONE IN PLASMA.

Authors:  S M GLICK; J ROTH; R S YALOW; S A BERSON
Journal:  Nature       Date:  1963-08-24       Impact factor: 49.962

3.  Carcinoma of the prostate: a clinical and steroid metabolic study.

Authors:  G BIRKE; C FRANKSSON; L O PLANTIN
Journal:  Acta Chir Scand       Date:  1955-06-18

4.  Hormone therapy in prostatic cancer.

Authors:  W F WHITMORE
Journal:  Am J Med       Date:  1956-11       Impact factor: 4.965

5.  A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma.

Authors:  D MATTINGLY
Journal:  J Clin Pathol       Date:  1962-07       Impact factor: 3.411

6.  Testosterone in human plasma.

Authors:  W S Coppage; A E Cooner
Journal:  N Engl J Med       Date:  1965-10-21       Impact factor: 91.245

7.  Effect of ethinyloestradiol on plasma testosterone levels and urinary testosterone excretion in man.

Authors:  E Forchielli; G S Rao; I R Sarda; N B Gibree; P E Pochi; J S Strauss; R I Dorfman
Journal:  Acta Endocrinol (Copenh)       Date:  1965-09

8.  Radioimmunoassay for human luteinizing hormone.

Authors:  W D Odell; G T Ross; P L Rayford
Journal:  Metabolism       Date:  1966-04       Impact factor: 8.694

9.  The estimation of testosterone in biological fluids. 1. Testosterone in plasma.

Authors:  B HUDSON; J COGHLAN; A DULMANIS; M WINTOUR; I EKKEL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-06
  9 in total
  7 in total

1.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

2.  Five-year clinical follow-up of prostatic cancer patients treated with fosfestrol and bromocriptine.

Authors:  L Jeromin; J Wiśniewski; M Rozniecki; Z Janiak; J Borkiewicz
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

3.  High-dose diethylstilbestrol diphosphate therapy of prostatic cancer after failure of standard doses of estrogens.

Authors:  P R Band; T K Banerjee; V C Patwardhan; T C Eid
Journal:  Can Med Assoc J       Date:  1973-10-20       Impact factor: 8.262

4.  Control of hormonal treatment of carcinoma of the prostate.

Authors:  J Frick
Journal:  Urol Res       Date:  1973-10

5.  The inhibition of deoxyribonucleic acid nucleotidyltransferase by stilboestrol derivatives.

Authors:  A R Fahmy; K Griffiths
Journal:  Biochem J       Date:  1968-08       Impact factor: 3.857

6.  Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.

Authors:  M R Robinson; B S Thomas
Journal:  Br Med J       Date:  1971-11-13

Review 7.  Glucocorticoids and prostate cancer treatment: friend or foe?

Authors:  Bruce Montgomery; Heather H Cheng; James Drechsler; Elahe A Mostaghel
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.